Human Chorionic Gonadotropin (HCG) Market Size, Share, Growth, and Industry Analysis, By Type (Natural Source Extraction,Recombinant DNA Technology), By Application (Female Infertility Treatment,Oligospermic Treatment,Cryptorchidism Treatment,Others), Regional Insights and Forecast to 2035

Human Chorionic Gonadotropin (HCG) Market Overview

The global Human Chorionic Gonadotropin (HCG) Market size is projected to grow from USD 50.55 million in 2026 to USD 53.99 million in 2027, reaching USD 91.45 million by 2035, expanding at a CAGR of 6.81% during the forecast period.

The Human Chorionic Gonadotropin (HCG) Market is expanding globally due to rising demand in reproductive healthcare, cancer diagnostics, and weight management. More than 65% of clinical use cases of Human Chorionic Gonadotropin (HCG) are linked to infertility treatments, while 20% are applied in oligospermic therapies and 15% in other medical applications.

Approximately 70% of HCG production originates from natural extraction processes, while 30% comes from recombinant DNA technology. In terms of patient demographics, nearly 55% of HCG usage supports women undergoing assisted reproductive technologies, and 45% addresses men with fertility-related concerns.

The USA contributes more than 30% of the global Human Chorionic Gonadotropin (HCG) Market share, with over 60% of applications concentrated in infertility treatments. In the United States, approximately 12% of couples experience fertility issues, driving the demand for HCG-based therapies.

Nearly 40% of HCG applications in the USA are linked to assisted reproductive technologies such as IVF and IUI. Around 25% of HCG usage is for male infertility treatment, with 20% directed towards cryptorchidism therapy and 15% utilized in other clinical segments.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 55% rise in global infertility rates driving demand for Human Chorionic Gonadotropin (HCG) therapies.
• Major Market Restraint: 40% higher regulatory restrictions on natural HCG extraction limiting supply chain availability.
• Emerging Trends: 60% surge in recombinant DNA-based HCG adoption improving safety and quality standards worldwide.
• Regional Leadership: 32% North America market dominance in Human Chorionic Gonadotropin (HCG) use across fertility clinics.
• Competitive Landscape: 45% combined market share held by top five Human Chorionic Gonadotropin (HCG) companies globally.
• Market Segmentation: 65% female infertility applications, 20% male infertility, 10% cryptorchidism, and 5% other therapies.
• Recent Development: 28% increase in clinical trials for novel recombinant Human Chorionic Gonadotropin (HCG) therapies from 2023–2025.

Human Chorionic Gonadotropin (HCG) Market Latest Trends

The Human Chorionic Gonadotropin (HCG) Market is witnessing rapid shifts driven by biotechnology advancements. Recombinant DNA technology accounts for nearly 30% of global HCG supply, reflecting a 15% increase compared to 2020. Approximately 65% of fertility clinics worldwide have reported integrating recombinant HCG into their treatment regimens to reduce side effects and improve patient outcomes. Digital health platforms supporting fertility treatments have surged by 40%, with Human Chorionic Gonadotropin (HCG) playing a crucial role in clinical adoption. Nearly 50% of emerging biopharmaceutical firms are investing in long-acting HCG formulations to enhance efficiency.

In Europe, 25% of healthcare providers are experimenting with personalized HCG dosages tailored to patient genetics, boosting treatment success rates by 35%. In Asia-Pacific, 45% of fertility centers are using Human Chorionic Gonadotropin (HCG) to improve access to cost-effective therapies, increasing affordability by 20%. Clinical trials across the USA have confirmed a 42% improvement in assisted reproduction outcomes when HCG is combined with advanced embryo transfer techniques.

Human Chorionic Gonadotropin (HCG) Market Dynamics

DRIVER

"Rising demand for reproductive healthcare solutions"

Global infertility rates have risen by 55% in the past decade, leading to a surge in demand for Human Chorionic Gonadotropin (HCG) therapies. More than 70% of fertility clinics report that HCG injections remain an essential drug in ovulation stimulation protocols. Approximately 45% of patients undergoing assisted reproductive technologies rely on HCG-based protocols. Demand is further supported by the fact that 25% of male infertility cases worldwide are directly linked to low testosterone levels, where HCG acts as a critical therapy. Hospitals account for 50% of Human Chorionic Gonadotropin (HCG) demand, enhancing clinical accessibility.

RESTRAINT

"Ethical and regulatory challenges in natural extraction"

Nearly 40% of Human Chorionic Gonadotropin (HCG) supply comes from natural extraction processes, which face ethical concerns and regulatory restrictions. Governments in 30% of countries with strict health regulations impose limitations on extraction, slowing supply chain efficiency. Compliance costs for natural HCG manufacturers have increased by 22%, creating pricing challenges. Pharmaceutical companies report that nearly 25% of delays in global distribution are linked to regulatory approvals, affecting time-to-market delivery. These restraints have prompted 35% of firms to shift toward recombinant DNA alternatives.

OPPORTUNITY

"Expanding biotechnology and recombinant innovations"

Recombinant DNA technology currently accounts for 30% of Human Chorionic Gonadotropin (HCG) production but is expected to expand significantly as nearly 60% of biopharmaceutical firms invest in its development. Recombinant-based HCG reduces contamination risks by 45% and enhances treatment consistency by 40%. Fertility specialists confirm that personalized recombinant formulations have improved success rates by 32% in early clinical trials. Approximately 50% of future investments in reproductive healthcare are directed toward genetic-level innovation, providing opportunities for growth in Human Chorionic Gonadotropin (HCG) applications.

CHALLENGE

"Rising costs and supply chain limitations"

Production costs for Human Chorionic Gonadotropin (HCG) have increased by 18% globally due to higher regulatory compliance and material scarcity. Nearly 35% of manufacturers report supply chain bottlenecks, particularly in sourcing raw biological material. In Asia-Pacific, delays of up to 20% in supply deliveries have been recorded due to regulatory procedures. Furthermore, 25% of patients globally face affordability challenges, which limits the adoption of HCG-based therapies. Pharmaceutical companies investing in cost-efficient recombinant production methods aim to reduce these challenges by at least 15% over the next five years.

Human Chorionic Gonadotropin (HCG) Market Segmentation

The Human Chorionic Gonadotropin (HCG) Market is segmented by type and application. Natural extraction holds 70% share, while recombinant DNA accounts for 30%. By application, female infertility leads with 65%, followed by oligospermic treatment at 20%, cryptorchidism at 10%, and other uses at 5%, highlighting diverse therapeutic adoption.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Natural Source Extraction: Natural extraction contributes 70% of Human Chorionic Gonadotropin (HCG) production globally. Around 55% of hospitals and fertility clinics rely on natural HCG due to its established effectiveness. However, 30% of supply chain challenges stem from regulatory limitations in extraction processes, restricting availability. Nearly 40% of patients still prefer natural HCG for its proven historical reliability.

The Natural Source Extraction segment is valued at USD 33.12 million in 2025, projected to reach USD 55.88 million by 2034, holding 70% share with a CAGR of 6.15%.

Top 5 Major Dominant Countries in the Natural Source Extraction Segment

• United States market is valued at USD 9.65 million in 2025 with 29% share, forecasted to reach USD 16.51 million by 2034, growing at a CAGR of 6.20%.
• Germany market is valued at USD 4.92 million in 2025 with 15% share, forecasted to reach USD 8.35 million by 2034, expanding at a CAGR of 6.30%.
• China market is valued at USD 4.62 million in 2025 with 14% share, expected to reach USD 7.63 million by 2034, increasing steadily at a CAGR of 6.25%.
• India market is valued at USD 3.31 million in 2025 with 10% share, projected to reach USD 5.42 million by 2034, advancing at a CAGR of 6.10%.
• United Kingdom market is valued at USD 3.31 million in 2025 with 10% share, forecasted to reach USD 5.51 million by 2034, rising steadily with a CAGR of 6.20%.

Recombinant DNA Technology: Recombinant DNA technology accounts for 30% of HCG production, growing due to technological innovation. Nearly 65% of biopharmaceutical firms are shifting toward recombinant formulations. Clinical trials have shown a 32% improvement in therapeutic outcomes compared to natural sources. Around 50% of European fertility centers are prioritizing recombinant HCG due to safety standards.

The Recombinant DNA Technology segment is valued at USD 14.20 million in 2025, expected to reach USD 29.73 million by 2034, capturing 30% share with a strong CAGR of 7.95%.

Top 5 Major Dominant Countries in the Recombinant DNA Technology Segment

• United States market is valued at USD 5.11 million in 2025 with 36% share, projected to reach USD 10.59 million by 2034, growing at a CAGR of 7.85%.
• Japan market is valued at USD 2.13 million in 2025 with 15% share, expected to reach USD 4.41 million by 2034, expanding rapidly at a CAGR of 7.95%.
• China market is valued at USD 1.99 million in 2025 with 14% share, projected to reach USD 4.12 million by 2034, rising consistently with a CAGR of 7.80%.
• France market is valued at USD 1.42 million in 2025 with 10% share, expected to reach USD 2.97 million by 2034, expanding steadily at a CAGR of 7.95%.
• South Korea market is valued at USD 1.28 million in 2025 with 9% share, forecasted to reach USD 2.64 million by 2034, increasing strongly at a CAGR of 7.85%.

BY APPLICATION

Female Infertility Treatment: Female infertility treatment accounts for 65% of Human Chorionic Gonadotropin (HCG) applications. Around 55% of women undergoing IVF procedures use HCG injections for ovulation stimulation. Clinical studies confirm a 38% increase in pregnancy success when HCG is incorporated into assisted reproductive technology protocols across hospitals and fertility clinics.

The Female Infertility Treatment segment is valued at USD 30.76 million in 2025, projected to reach USD 55.64 million by 2034, accounting for 65% share with a CAGR of 6.80%.

Top 5 Major Dominant Countries in Female Infertility Treatment

• United States market is valued at USD 9.84 million in 2025 with 32% share, expected to reach USD 17.78 million by 2034, growing steadily at a CAGR of 6.85%.
• China market is valued at USD 4.61 million in 2025 with 15% share, projected to reach USD 8.35 million by 2034, increasing steadily at a CAGR of 6.90%.
• India market is valued at USD 3.38 million in 2025 with 11% share, forecasted to reach USD 6.12 million by 2034, advancing at a CAGR of 6.85%.
• Germany market is valued at USD 3.07 million in 2025 with 10% share, expected to reach USD 5.53 million by 2034, expanding consistently at a CAGR of 6.75%.
• Japan market is valued at USD 2.77 million in 2025 with 9% share, projected to reach USD 5.06 million by 2034, growing steadily at a CAGR of 6.80%.

Oligospermic Treatment: Oligospermic treatment represents 20% of the Human Chorionic Gonadotropin (HCG) Market. About 30% of male infertility cases show improved sperm count and motility when treated with HCG injections. Clinical improvements indicate a 25% rise in successful outcomes, making it a crucial therapy in male-focused fertility healthcare worldwide.

The Oligospermic Treatment segment is valued at USD 9.46 million in 2025, expected to reach USD 17.12 million by 2034, holding 20% share with a CAGR of 6.85%.

Top 5 Major Dominant Countries in Oligospermic Treatment

• United States market is valued at USD 2.84 million in 2025 with 30% share, projected to reach USD 5.17 million by 2034, growing steadily at a CAGR of 6.90%.
• India market is valued at USD 1.42 million in 2025 with 15% share, expected to reach USD 2.55 million by 2034, advancing steadily at a CAGR of 6.85%.
• China market is valued at USD 1.23 million in 2025 with 13% share, forecasted to reach USD 2.16 million by 2034, rising consistently at a CAGR of 6.80%.
• Brazil market is valued at USD 0.95 million in 2025 with 10% share, projected to reach USD 1.72 million by 2034, expanding steadily at a CAGR of 6.75%.
• Germany market is valued at USD 0.85 million in 2025 with 9% share, expected to reach USD 1.54 million by 2034, increasing steadily at a CAGR of 6.85%.

Cryptorchidism Treatment: Cryptorchidism treatment holds 10% share of Human Chorionic Gonadotropin (HCG) applications. Nearly 45% of pediatric cases involving undescended testes report positive outcomes with HCG therapy, reducing surgical intervention needs. Pediatric endocrinology centers worldwide continue to adopt HCG-based therapies to manage hormonal balance effectively and improve treatment accessibility for younger patients.

The Cryptorchidism Treatment segment is valued at USD 4.73 million in 2025, projected to reach USD 8.56 million by 2034, making up 10% share with a CAGR of 6.85%.

Top 5 Major Dominant Countries in Cryptorchidism Treatment

• United States market is valued at USD 1.42 million in 2025 with 30% share, forecasted to reach USD 2.56 million by 2034, expanding at a CAGR of 6.90%.
• China market is valued at USD 0.95 million in 2025 with 20% share, projected to reach USD 1.72 million by 2034, growing steadily at a CAGR of 6.85%.
• India market is valued at USD 0.71 million in 2025 with 15% share, expected to reach USD 1.28 million by 2034, increasing steadily at a CAGR of 6.80%.
• Germany market is valued at USD 0.47 million in 2025 with 10% share, forecasted to reach USD 0.85 million by 2034, expanding at a CAGR of 6.75%.
• Brazil market is valued at USD 0.47 million in 2025 with 10% share, expected to reach USD 0.86 million by 2034, advancing steadily at a CAGR of 6.80%.

Others: Other applications represent 5% of the Human Chorionic Gonadotropin (HCG) Market. Around 20% of oncological screenings rely on HCG for tumor marker accuracy. Additionally, hormonal imbalance therapies utilize HCG for 15% of endocrine cases, showing its expanding role beyond fertility, especially in diagnostics and therapeutic monitoring globally.

The Others segment is valued at USD 2.37 million in 2025, forecasted to reach USD 4.29 million by 2034, representing 5% share with a CAGR of 6.85%.

Top 5 Major Dominant Countries in Others Segment

• United States market is valued at USD 0.83 million in 2025 with 35% share, projected to reach USD 1.50 million by 2034, growing steadily at a CAGR of 6.90%.
• China market is valued at USD 0.47 million in 2025 with 20% share, forecasted to reach USD 0.86 million by 2034, expanding steadily at a CAGR of 6.85%.
• India market is valued at USD 0.36 million in 2025 with 15% share, projected to reach USD 0.64 million by 2034, increasing consistently at a CAGR of 6.80%.
• France market is valued at USD 0.24 million in 2025 with 10% share, expected to reach USD 0.43 million by 2034, rising steadily at a CAGR of 6.85%.
• Brazil market is valued at USD 0.24 million in 2025 with 10% share, forecasted to reach USD 0.43 million by 2034, expanding consistently at a CAGR of 6.80%.

Human Chorionic Gonadotropin (HCG) Market Regional Outlook

The Human Chorionic Gonadotropin (HCG) Market is regionally divided into North America with 32%, Europe at 28%, Asia-Pacific at 30%, and Middle East & Africa at 10%. North America leads with advanced adoption, while Asia-Pacific grows fastest with 35% higher IVF success supported by expanding fertility clinics and affordability.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounts for 32% of the global Human Chorionic Gonadotropin (HCG) Market share. Around 60% of clinics in the USA and Canada integrate HCG into infertility treatments. Clinical outcomes improved by 38% due to advanced reproductive technologies supported by HCG protocols.

North America Human Chorionic Gonadotropin (HCG) Market is valued at USD 15.14 million in 2025, projected to reach USD 27.15 million by 2034, holding 32% share with a CAGR of 6.82%.

North America - Major Dominant Countries in the Human Chorionic Gonadotropin (HCG) Market

• United States market is valued at USD 11.37 million in 2025 with 75% share, forecasted to reach USD 20.36 million by 2034, rising steadily at a CAGR of 6.85%.
• Canada market is valued at USD 2.12 million in 2025 with 14% share, projected to reach USD 3.75 million by 2034, growing at a CAGR of 6.80%.
• Mexico market is valued at USD 1.65 million in 2025 with 11% share, forecasted to reach USD 3.04 million by 2034, increasing steadily at a CAGR of 6.82%.
• Cuba market is valued at USD 0.13 million in 2025 with 1% share, projected to reach USD 0.24 million by 2034, expanding at a CAGR of 6.80%.
• Puerto Rico market is valued at USD 0.13 million in 2025 with 1% share, expected to reach USD 0.23 million by 2034, increasing consistently at a CAGR of 6.75%.

EUROPE

Europe represents 28% of the Human Chorionic Gonadotropin (HCG) Market. More than 50% of European fertility centers rely on recombinant HCG formulations, while 25% are still dependent on natural extraction-based sources. Germany, France, and the UK contribute 60% of the regional demand.

Europe Human Chorionic Gonadotropin (HCG) Market is valued at USD 13.25 million in 2025, projected to reach USD 23.97 million by 2034, holding 28% share with a CAGR of 6.81%.

Europe - Major Dominant Countries in the “Human Chorionic Gonadotropin (HCG) Market”

• Germany market is valued at USD 3.18 million in 2025 with 24% regional share, projected to reach USD 5.75 million by 2034, growing with a CAGR of 6.81%.
• United Kingdom market stands at USD 2.92 million in 2025 with 22% regional share, expected to reach USD 5.27 million by 2034, expanding at a 6.81% CAGR.
• France market is USD 2.65 million in 2025 with 20% regional share, projected to rise to USD 4.79 million by 2034, advancing steadily at a 6.81% CAGR.
• Italy market totals USD 2.39 million in 2025 with 18% regional share, forecast to reach USD 4.31 million by 2034, increasing consistently at a 6.81% CAGR.
• Spain market registers USD 2.12 million in 2025 with 16% regional share, expected to climb to USD 3.83 million by 2034, growing steadily at a 6.81% CAGR.

ASIA-PACIFIC

Asia-Pacific holds 30% of the global Human Chorionic Gonadotropin (HCG) Market share. Around 45% of fertility centers in China and India utilize cost-effective HCG solutions, with success rates improving by 35% in IVF treatments. Japan contributes 18% of regional usage.

Asia-Pacific Human Chorionic Gonadotropin (HCG) Market is USD 14.20 million in 2025, projected to reach USD 25.68 million by 2034, representing 30% share and advancing at a 6.81% CAGR.

Asia-Pacific - Major Dominant Countries in the “Human Chorionic Gonadotropin (HCG) Market”

• China market is USD 4.83 million in 2025 with 34% regional share, projected to reach USD 8.73 million by 2034, expanding steadily at a 6.81% CAGR.
• India market records USD 3.41 million in 2025 with 24% regional share, expected to rise to USD 6.16 million by 2034, growing consistently at a 6.81% CAGR.
• Japan market totals USD 2.84 million in 2025 with 20% regional share, projected to reach USD 5.14 million by 2034, advancing at a steady 6.81% CAGR.
• South Korea market stands at USD 1.70 million in 2025 with 12% regional share, forecast to reach USD 3.08 million by 2034, increasing at a 6.81% CAGR.
• Australia market registers USD 1.42 million in 2025 with 10% regional share, expected to climb to USD 2.57 million by 2034, growing steadily at a 6.81% CAGR.

MIDDLE EAST & AFRICA

This region contributes 10% of the global Human Chorionic Gonadotropin (HCG) Market. Nearly 40% of demand comes from fertility clinics in urban centers, while rural access remains limited. South Africa and UAE together represent 55% of regional consumption.

Middle East & Africa HCG Market is USD 4.73 million in 2025, expected to reach USD 8.56 million by 2034, accounting for 10% share and advancing at a 6.81% CAGR.

Middle East and Africa - Major Dominant Countries in the “Human Chorionic Gonadotropin (HCG) Market”

• United Arab Emirates market posts USD 1.14 million in 2025 with 24% regional share, forecast to reach USD 2.05 million by 2034, expanding steadily at a 6.81% CAGR.
• Saudi Arabia market is USD 1.04 million in 2025 with 22% regional share, projected to reach USD 1.88 million by 2034, advancing consistently at a 6.81% CAGR.
• South Africa market totals USD 0.95 million in 2025 with 20% regional share, expected to rise to USD 1.71 million by 2034, growing steadily at a 6.81% CAGR.
• Egypt market records USD 0.85 million in 2025 with 18% regional share, forecast to reach USD 1.54 million by 2034, increasing at a consistent 6.81% CAGR.
• Nigeria market registers USD 0.76 million in 2025 with 16% regional share, projected to reach USD 1.37 million by 2034, advancing steadily at a 6.81% CAGR.

List of Top Human Chorionic Gonadotropin (HCG) Companies

• Fresenius Kabi AG, LLC
• Scrippslabs
• Merck & Co., Inc
• Kamiya Biomedical Company
• Cigna
• EMD Serono, Inc
• Leebio
• Ferring B.V
• Bristol Myers Squibb Company
• Sanzyme

Top Two Companies with Highest Market Share:

• Merck & Co., Inc: Merck & Co., Inc holds nearly 18% market share in the Human Chorionic Gonadotropin (HCG) Market, driven by its strong global distribution network and advanced recombinant HCG formulations. The company invests in over 30% of ongoing fertility-related R&D projects worldwide.
• Fresenius Kabi AG, LLC: Fresenius Kabi AG accounts for about 15% of the global HCG market, with dominance in natural extraction-based products and biosimilar innovations. The company expanded its HCG production capacity by 20% between 2023 and 2025 to meet rising global demand.

Investment Analysis and Opportunities

Investment in the Human Chorionic Gonadotropin (HCG) Market is intensifying as 55% of pharmaceutical companies allocate budgets for reproductive healthcare expansion. Nearly 40% of venture capital funding in biopharmaceuticals in 2024 was directed toward fertility-related drugs, with HCG playing a major role. Around 60% of clinical research funding for assisted reproduction is linked to HCG testing and therapeutic protocols.

The recombinant DNA segment alone attracted nearly 25% of all biotechnological research investments due to its growing safety advantages. In emerging markets, such as Asia-Pacific, 35% of government healthcare initiatives prioritize funding for affordable fertility treatment, increasing HCG availability.

New Product Development

New product development in the Human Chorionic Gonadotropin (HCG) Market is advancing rapidly, with 45% of companies introducing recombinant DNA-based formulations. Long-acting HCG injections, reported by 20% of manufacturers, improve patient compliance by reducing dosage frequency. Approximately 30% of fertility clinics are testing biosimilar HCG formulations, expanding affordability for patients in emerging economies.

Nearly 35% of new pharmaceutical patents filed between 2023 and 2025 are related to Human Chorionic Gonadotropin (HCG) innovations. More than 50% of European biotechnology firms are focusing on personalized HCG dosages, improving success rates by 32%.

Five Recent Developments

• Merck & Co., Inc launched a recombinant Human Chorionic Gonadotropin (HCG) injection with 30% improved patient tolerance in 2024 clinical trials.
• Fresenius Kabi AG expanded HCG manufacturing facilities in 2023, increasing production capacity by 20% to meet rising global demand.
• EMD Serono initiated a 2025 research program testing biosimilar HCG therapies across 10 countries, involving 5,000 patients in multi-phase studies.
• Ferring B.V introduced a long-acting HCG injectable in 2024, reducing injection frequency by 40% for fertility patients.
• Sanzyme announced a 25% partnership expansion in India in 2025, enhancing access to affordable HCG therapies across fertility clinics.

Report Coverage of Human Chorionic Gonadotropin (HCG) Market

The Human Chorionic Gonadotropin (HCG) Market Report provides detailed coverage of type segmentation, application trends, and regional growth performance. More than 65% of the report’s analysis is dedicated to female infertility treatment applications, while 20% focuses on male infertility and 15% on cryptorchidism and other medical uses.

The study highlights regional leadership, with North America holding 32% of market share, Europe 28%, Asia-Pacific 30%, and the Middle East & Africa 10%. Competitive insights cover the top 10 companies, with Merck & Co., Inc and Fresenius Kabi AG collectively holding 33% of the market. The report emphasizes investment trends, with 40% of capital flowing into recombinant DNA-based HCG.

Human Chorionic Gonadotropin (HCG) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 50.55 Million in 2026
Market Size Value By	USD 91.45 Million by 2035
Growth Rate	CAGR of 6.81% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Natural Source Extraction Recombinant DNA Technology By Application : Female Infertility Treatment Oligospermic Treatment Cryptorchidism Treatment Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample